CORRECTION Open Access

Correction to: *Linc-SCRG1* accelerates progression of hepatocellular carcinoma as a ceRNA of miR26a to derepress SKP2



Jun-Jie Hu[†], Cui Zhou[†], Xin Luo[†], Sheng-Zheng Luo, Zheng-Hong Li, Zi-Xin Xu and Ming-Yi Xu^{*}

Correction to: J Exp Clin Cancer Res 40, 26 (2021) https://doi.org/10.1186/s13046-020-01825-2

Following publication of the original article [1], the authors identified minor errors in image-typesetting in Fig. 2, Fig. 4 and Fig. 6; specifically:

- Figure 2E: the western blot figure of GAPDH of SNU-387 (row 4) was incorrectly used; the correct image has now been used
- Figure 2E: the label of groups of western blot was incorrect; the correct label has now been used
- Figure 4B: during the production process, image distortion was introduced in the colony study of Hep3B cells; this has been corrected using the originally provided image files
- Figure 4E: the western blot figure of E-cadherin of SNU-387 was incorrectly used; the correct image has now been used
- Figure 4E: the label of groups of western blot was incorrect; the correct label has now been used
- Figure 6B: during the production process, image distortion was introduced in the colony study of Hep3B cells; this has been corrected using the originally provided image files
- Figure 6D: the transwell figures of sh-lincSCRG1 + ov-SKP2 (row 3) and sh-lincSCRG1 + in-miR26a

(row 4) groups of SNU-387 and Hep3B were incorrectly used; the correct images have now been used

The corrected figures are given below. The corrections do not have any effect on the results or conclusions of the paper. The original article has been corrected.

Published online: 25 May 2021

Reference

 Hu JJ, Zhou C, Luo X, Luo SZ, Li ZH, Xu ZX, et al. Linc-SCRG1 accelerates progression of hepatocellular carcinoma as a ceRNA of miR26a to derepress SKP2. J Exp Clin Cancer Res. 2021;40(1):26. https://doi.org/10.1186/s13046-02 0-01825-2

The original article can be found online at https://doi.org/10.1186/s13046-020-01825-2.

[†]Jun-Jie Hu, Cui Zhou and Xin Luo contributed equally to this work. Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No 100, Haining Rd, Shanghai 200080,



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*} Correspondence: xumingyi2014@163.com




Fig. 2 Overexpression of lincSCRG1 dramatically promoted HCC cell proliferation and migration in vitro. Sh-lincSCRG1, sh-NC (in SNU-387 cells), ov-lincSCRG1 and ov-vector (in Hep3B cells) cell lines were established. **a** Cell viability was examined by MTT assays. **b** Oncogenic survival was assessed by colony formation assays. **c** Cell cycle proliferation was evaluated by flow cytometry. **d** Migration was determined by transwell assays. **e** Cell cycle-related proteins (CKD4/6 and cyclinD1) and EMT-related proteins (MMP-2/3/9, E-cadherin, N-cadherin and Vimentin) were examined by western blot analysis. In (**a-e**), */**/***indicates vs. The ov-vector/sh-NC group (*, p < 0.05, **, p < 0.01, ***, p < 0.001)




Fig. 4 MiR26a is negatively correlated with the proliferation and migration of HCC in vitro. Mi-miR26a, mi-NC (in SNU-387 cells), in-miR26a and in-NC (in Hep3B cells) cell lines were established. **a** Cell viability was examined by MTT assays. **b** Oncogenic survival was assessed by colony formation assays. **c** Cell cycle proliferation was evaluated by flow cytometry. **d** Migration was determined by transwell assays. **e** Cell cycle-related proteins (CKD4/6 and cyclinD1) and EMT-related proteins (MMP-2/3/9, E-cadherin, N-cadherin and Vimentin) were examined by western blot analysis. In (**a-e**), */**/***indicates vs. The mi-NC/in-NC group (*, p < 0.05, **, p < 0.001)




Fig. 6 *LincSCRG1* promotes cell proliferation and migration of HCC via regulating the miR26a/SKP2 axis in vitro. Sh-NC, sh-*lincSCRG1*, sh-*lincSCRG1* + ov-SKP2 and sh-*lincSCRG1* + in-miR26a groups were established in SNU-387 and Hep-3B cell lines. **a** Cell viability was examined by MTT assays. **b** Oncogenic survival was assessed by colony formation assays. **c** Cell cycle proliferation was evaluated by flow cytometry. **d** Migration was determined by transwell assays. **e** Cell cycle-related proteins (CKD4/6 and cyclinD1) and EMT-related proteins (MMP-2/3/9, E-cadherin, N-cadherin and Vimentin) were examined by western blot analysis. In (**a** - **d**) */#/& indicatesthe sh-*lincSCRG1* vs. sh-NC group, the sh-*lincSCRG1* + ov-SKP2 vs. sh-*lincSCRG1* -group, and the sh-*lincSCRG1* + in-miR26a vs. sh-*lincSCRG1* group, respectively (n = 6). * /#/&, p < 0.05, ***/##/&&&, p < 0.001